

Application No.: 09/657,336

2

Docket No.: 500862001500

AMENDMENTS TO THE CLAIMS

Claim 1 (Currently amended): An modified anti-viral peptide-albumin conjugate comprising

a peptide having been modified to contain an anti-viral peptide comprising a maleimide containing group which is reactive with cysteine 34 of serum albumin to form a stable covalent bond, said peptide comprising and an amino acid sequence wherein said sequence is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545, wherein said sequence exhibits an anti-viral activity against human immunodeficiency virus (HTV) wherein and said peptide is covalently bonded to cysteine 34 of serum albumin through said maleimide containing group to form said peptide-albumin conjugate, wherein the ratio of peptide to serum albumin in said conjugate is 1:1.

Claim 2 (canceled)

Claim 3 (canceled)

Claim 4 (Currently amended) The modified anti-viral peptide-albumin conjugate of claim 1 wherein said peptide is DP-107 and comprises the amino acid sequence [[of]] is SEQ ID NO:2.

Claim 5 (canceled)

Claim 6 (Currently amended): The modified anti-viral peptide-albumin conjugate of claim 1 wherein said peptide amino acid sequence is selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545.

Claims 7-18 (canceled)

sf-2088911

Application No.: 09/657,336

3

Docket No.: 500862001500

Claim 19 (Currently amended): A composition for use in the prevention and/or treatment of acquired immune deficiency syndrome (AIDS) comprising, in a physiologically acceptable medium, an modified anti-viral peptide-albumin conjugate including a peptide having been modified to contain a comprising an anti-viral peptide comprising a maleimide containing group and which is reactive with cysteine 34 of serum albumin to form a stable covalent bond, said peptide comprises an amino acid sequence wherein said sequence is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545, wherein said sequence exhibiting exhibits an anti-viral activity against human immunodeficiency virus (HIV) wherein and said peptide is covalently bonded to cysteine 34 of serum albumin through said maleimide containing group to form said anti-viral peptide-albumin conjugate, wherein the ratio of peptide to serum albumin in said conjugate is 1:1.

Claim 20 (canceled)

Claim 21 (Currently amended): The composition of claim 20 19 wherein said peptide is DP 107 comprising the amino acid sequence [[of]] is SEQ ID NO:2.

Claims 22-30 (canceled)

Claim 31 (Currently amended): The composition of claim 19 wherein said peptide comprises an amino acid sequence is selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545.

Claims 32-35 (canceled)

Claim 36 (Currently amended): A composition comprising the modified anti-viral peptide-albumin conjugate of claim 1 in a physiologically acceptable medium.

Claim 37 (canceled)

sf-2088911

Application No.: 09/657,336

4

Docket No.: 500862001500

Claim 38 (Currently amended): The composition of claim 36 wherein said ~~modified anti-viral peptide~~ comprises the amino acid sequence ~~[[of]]~~ is SEQ ID NO:2.

Claim 39 (Currently amended): The composition of claim 36 wherein said ~~modified anti-viral peptide~~ comprises an amino acid sequence ~~is~~ selected from the group consisting of SEQ ID NO:147, SEQ ID NO:148, SEQ ID NO:149, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:542, SEQ ID NO:543, SEQ ID NO:544, and SEQ ID NO:545.

Claim 40-55 (canceled)

Please add the following new claims:

Claim 56 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:147.

Claim 57 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:148.

Claim 58 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:149.

Claim 59 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:179.

Claim 60 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:180.

Claim 61 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:181.

Claim 62 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:542.

sf-2088911

Application No.: 09/657,336

5

Docket No.: 500862001500

Claim 63 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:543.

Claim 64 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:544.

Claim 65 (new): The anti-viral peptide-albumin conjugate of claim 1 wherein said amino acid sequence is SEQ ID NO:545.

Claim 66 (new): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:147.

Claim 67 (new): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:148.

Claim 68 (new): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:149.

Claim 69 (new): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:179.

Claim 70 (new): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:180.

Claim 71 (new): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:181.

Claim 72 (new): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:542.

Claim 73 (new): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:543.

sf-2088911

Application No.: 09/657,336

6

Docket No.: 500862001500

Claim 74 (new): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:544.

Claim 75 (new): The composition of claim 19 wherein said amino acid sequence is SEQ ID NO:545.

sf-2088911